Cochrane · systematic review · CD008296
Paliperidone palmitate for schizophrenia
Nussbaum, AM, Stroup, TS · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 14.3%Moderate 4 · 28.6%High 5 · 35.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Paliperidone palmitate compared to placebo for people with schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early ‐ any reason Reported by trial author Paliperidone palmitate vs placebo | RR 0.76 [7, 84] | 5 studies · 2183 participants | High |
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial Paliperidone palmitate vs placebo | RR 0.79 [0.74, 0.85] | 4 studies · 1696 participants | Moderate Downgraded: indirectness |
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event Paliperidone palmitate vs placebo | RR 0.56 [0.46, 0.7] | 5 studies · 2084 participants | Moderate |
Average change in prolactin in men Serum prolactin level (ng/mL) Paliperidone palmitate vs placebo | no estimate extracted | 5 studies · 1418 participants | High |
Average change in prolactin in women Serum prolactin level (ng/mL) Paliperidone palmitate vs placebo | no estimate extracted | 5 studies · 764 participants | High |
Average change in weight Change in weight (kg) from beginning to end of trial Paliperidone palmitate vs placebo | no estimate extracted | 5 studies · 2052 participants | High |
Health‐related quality of life ‐ not measured Paliperidone palmitate vs placebo | no estimate extracted | NR | No studies |
Paliperidone palmitate compared to risperidone long‐acting injection for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early ‐ any reason Reported by trial author Paliperidone palmitate vs risperidone long‐acting injection | RR 1.12 [1, 1.25] | 2 studies · 1969 participants | High |
Leaving the study early ‐ lack of efficacy Reported by trial author Paliperidone palmitate vs risperidone long‐acting injection | RR 1.35 [1.06, 1.71] | 2 studies · 1969 participants | Moderate |
Death Reported by trial author Paliperidone palmitate vs risperidone long‐acting injection | RR 3.62 [0.6, 21.89] | 2 studies · 1967 participants | Low |
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial Paliperidone palmitate vs risperidone long‐acting injection | RR 1.03 [0.93, 1.14] | 2 studies · 1587 participants | Low Downgraded: indirectness |
Relapse: recurrence of psychotic symptoms Reported by trial authors as adverse event Paliperidone palmitate vs risperidone long‐acting injection | RR 1.23 [0.98, 1.53] | 2 studies · 1961 participants | Moderate |
Cost ‐ not measured Paliperidone palmitate vs risperidone long‐acting injection | no estimate extracted | NR | No studies |
Health related quality of life ‐ not measured Paliperidone palmitate vs risperidone long‐acting injection | no estimate extracted | NR | No studies |